Early cardiotoxicity induced by treatment of hematologic malignancies and the risk-factors of its manifestation.

The aim of the study was to determine the incidence of early cardiotoxicity, induced by the treatment of Hemoblastosis and its dependence on the summary dose of antracyclins and other risk-factors (age, sex, pre-existing cardiac diseases). The study revealed that the summary dose of antracyclins is the important risk-factor of cardiotoxicity development. Cardiotoxicity was evident when applying > or =200 mg/m(2) and < or =200 mg/m(2) doses. The age, above 50, and pre-existing cardiovascular diseases, play a vital role. The incidence of the above changes was significantly higher in female patients than in male ones. Co-existence of different risk-factors further complicates the condition; such cases need deeper understanding, dynamic monitoring and early correction.